NanoMark
Detection of Solid Tumors
Pre-clinicalActive
Key Facts
About Kuva Labs
Kuva Labs is a private, pre-revenue biotech founded in 2020, focused on revolutionizing cancer diagnostics through its novel MRI imaging agent, NanoMark. The technology promises high-contrast, high-resolution imaging of solid tumors without radioactivity, targeting only cancer cells and providing quantitative data. The company addresses a critical need for earlier and more accurate cancer detection to improve treatment success rates and reduce healthcare costs, though its platform is still in the pre-clinical or early development stage.
View full company profile